Form 4: AXIM Biotechnologies Director Acquires Convertible Note
SEC Form 4 Filing
Director Timothy R. Scott acquired a convertible note worth $35,000, which can be converted into 3,500,000 shares of AXIM Biotechnologies common stock at $0.01 per share.
Summary
- On March 15, 2024, Timothy R. Scott, a director of AXIM Biotechnologies, acquired a convertible note with a face value of $35,000.
- The note can be converted into 3,500,000 shares of AXIM Biotechnologies' common stock at a conversion price of $0.01 per share.
- Following the transaction, Mr. Scott directly owns 4,500,000 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It's neither overtly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, buy or sell their company's stock. This filing indicates a director's increased investment in the company.
Stakeholder Impact
- The acquisition of a convertible note by a director could be viewed positively by shareholders as it signals confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of the transaction: Director Timothy R. Scott acquired a convertible note. |
| 03/15/2024 | Convertible note is exercisable. |
| 03/01/2034 | Convertible note expiration date. |
| 03/18/2024 | Date of signature for the Form 4 filing. |
Keywords
AXIM Biotechnologies, Convertible Note, Director, Form 4, Beneficial Ownership, Scott, Timothy R. Scott
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.